Close
Almac
Achema middle east

Press Releases

Almac Introduces selectAZyme

Almac’s biocatalysis business has expanded from its 2009 launch with the sale of six enzyme screening kits, to the current supply of 100s of kgs of chiral intermediates for drug substance manufacture, regular enzyme supply to specialty chemical companies...

ISTA Pharmaceuticals Reports Positive, Topline Results From Its Phase 2 Clinical Trial of Bepotastine Besilate Nasal Spray

ISTA Pharmaceuticals, Inc. announced positive, topline results from its Phase 2 dose-ranging, environmental clinical trial of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies....

Wockhardt receives US FDA approval for generic version of Aricept tablets

Pharmaceutical and biotechnology major Wockhardt has received tentative approval from the United States Food & Drug Administration (US FDA) for marketing 5mg and 10mg tablets of Donepezil HCl, which is used for treatment of Alzheimer’s disease and dementia. Donepezil...

CIT/ABC acquires assets of LAB Research Inc.

Applied Biology Company (ABC), the holding company of CIT Safety & Health Research Laboratories (CIT), a leading player among European preclinical CROs, announces today the purchase of substantially all of the assets of LAB Research Inc. (LAB Research), consisting...

AMRI Announces Development and Commercial Supply Agreement with Parnell Manufacturing

AMRI announced that it has entered into a development and long term exclusive commercial supply agreement with Parnell Manufacturing Pty Ltd (Parnell), an Australian company specializing in the research, development and manufacture of veterinary products. Under...

Lundbeck’s partner Mochida receives approval of Lexapro in Japan

H. Lundbeck A/S announced that our partner Mochida Pharmaceutical Co., Ltd. (Mochida) has obtained approval of Lexapro® 10 mg (escitalopram) from the Japanese Ministry of Health, Labour and Welfare (MHLW). Lundbeck has partnered...

Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851

Amgen and UCB announced positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO). This...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »